Healthcare Economist December 11, 2024
That is a key question if long-run drug prices are going to come down for biologic products. We can decompose this question into 3 sub-questions:
- What share patients initiating therapy start on a biosimilar?
- What share of patients already using a biologic products switch to a biosimilar?
- Do patient of physician factors drive biosimilar prescribing patterns?
A paper by Roberts et al. (2024) aims to answer these questions using the medication infliximab as a case study. Infliximab is indicated for a variety of auto-immune diseases (e.g., rheumatoid arthritis, Crohn’s disease, psoriatic arthritis).
Methods
The authors use data from the American College of Rheumatology’s Rheumatology Informatics System for Effectiveness (RISE) registry. RISE is drawn from electronic health records data...
Today's Sponsors
Today's Sponsor